Earnings per Share (Tables)

3 Months Ended

Mar. 28, 2025

Earnings Per Share [Abstract]

Schedule of Earnings per Share

The weighted-average number of shares outstanding used in the computations of both basic and diluted loss per share were as follows (in millions):

	Three Months Ended
	March 28, 2025	March 29, 2024
Basic and diluted	19.7	19.7

A net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per share are the same. If the Company records net income in the future, the denominator of a diluted earnings per share calculation will include both the weighted average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Approximately 1.7 million and 1.8 million of contingent value rights held by the Opioid Master Disbursement Trust II and outstanding equity awards for the three months ended March 28, 2025 and March 29, 2024, respectively, could potentially dilute per share amounts in the future.